13G Filing: Jafco Sv4 Investment Limited Partnership and Miragen Therapeutics Inc. (NASDAQ:MGEN)

CUSIP No. 60463E103

Page 5 of 8

ITEM 4. OWNERSHIP.

Provide the following information regarding
the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially
owned: 1,160,406 shares

(b) Percent of class:
5.4%

(c) Number of shares
as to which such person has:

(i) Sole power
to vote or to direct the vote: 1,160,406 shares (See Row 5 of cover page for each Reporting Person.)

(ii) Shared power
to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii) Sole power
to dispose or to direct the disposition of: 1,160,406 shares (See Row 7 of cover page for each Reporting Person.)

(iv) Shared power
to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

The percentages used
herein are calculated based on 21,370,063 shares of Common Stock reported by Miragen Therapeutics, Inc. issued and outstanding
as of March 17, 2017, as disclosed on the cover page of its Annual Report on Form 10-K, as filed with the Securities
and Exchange Commission on or about March 24, 2017.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR
LESS OF A CLASS.

Not applicable.

ITEM 6. OWNERSHIP OF MORE THAN FIVE
PERCENT ON BEHALF OF ANOTHER PERSON.

Not Applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION
OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

Not Applicable.